Statement of Organization, Functions, and Delegations of Authority, 9136 [06-1642]
Download as PDF
<![CDATA[
9136
Federal Register / Vol. 71, No. 35 / Wednesday, February 22, 2006 / Notices
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions; (3) Ways
to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
For Further Information Contact: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Christy Thomsen,
Director, Office of Communications and
Public Liaison, NCCAM, 31 Center
Drive, Room 2B11, Bethesda, MD
20892–2182; or fax your request to 301–
402–4741; or e-mail
thomsenc@mail.nih.gov. Ms. Thomsen
can be contacted by telephone at 301–
451–8876.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: February 14, 2006.
Christy Thomsen,
Director, Office of Communications and
Public Liaison, National Center for
Complementary and Alternative Medicine,
National Institutes of Health.
[FR Doc. E6–2507 Filed 2–21–06; 8:45 am]
Delegations of Authority
All delegations and redelegations of
authority to officers and employees of
NIH that were in effect immediately
prior to the effective date of this
amendment and are consistent with this
amendment shall continue in effect,
pending further redelegation.
BILLING CODE 4167–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
cprice-sewell on PROD1PC66 with NOTICES
Statement of Organization, Functions,
and Delegations of Authority
Part N, National Institutes of Health,
of the Statement of Organization,
Functions, and Delegations of Authority
for the Department of Health and
Human Services (HHS) (40 FR 22859,
May 27, 1975, as amended most recently
at 69 FR 64081, November 3, 2004, and
redesignated from Part HN as Part N at
60 FR 56606, November 9, 1995), is
amended as set forth below to reflect the
reorganization of the National Human
Genome Research Institute, Division of
Intramural Research, by establishing (1)
the Molecular Neurogenetics Section in
the Medical Genetics Branch and (2) the
VerDate Aug<31>2005
14:35 Feb 21, 2006
Jkt 208001
Vascular Biology Section in the Genome
Technology Branch. The sections are
transferring from, respectively, the
National Heart, Lung, and Blood
Institute and the National Institute of
Mental Health.
Section N–B, Organization and
Functions, under the heading National
Human Genome Research Institute (N4,
formerly HN4), Division of Intramural
Research (N45, formerly HN45) is
amended as follows:
(1) In the Genome Technology Branch
(N455, formerly HN455), immediately
after the paragraph on Genomic
Functional Analysis Section (N4556,
formerly HN 4556), insert the following:
Vascular Biology Section (N4557,
formerly HN 4557). Conducts clinical
and laboratory investigations in the
molecular mechanisms of
cardiovascular disease including
vascular cell biology, gene therapy, and
cell cycle regulation of vascular cells.
(2) In the Medical Genetics Branch
(N456, formerly HN456), immediately
after the paragraph on Vertebrate
Embryology Section (N4567, formerly
HN4567), insert the following:
Molecular Neurogenetics Section
(N4568, formerly HN 4568). (1)
Conducts clinical and basic research
into the factors contributing to the
phenotypic variation observed in
monogenic diseases, using Gaucher
disease as a prototype disorder; (2)
investigates the relationship between
Gaucher disease and parkinsonism; and
(3) explores new therapeutic approaches
for Gaucher disease.
Dated: February 8, 2006.
Elias A. Zerhouni,
Director, National Institutes of Health.
[FR Doc. 06–1642 Filed 2–21–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the paperwork
Reduction Act of 1995 concerning
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Mandatory
Guidelines for Federal Workplace Drug
Testing Programs (OMB NO. 0930–
0158)—Revision
SAMHSA’s Mandatory Guidelines for
Federal Workplace Drug Testing
Programs will request OMB approval for
the Federal Drug Testing Custody and
Control Form for Federal agency and
federally regulated drug testing
programs which must comply with the
HHS Mandatory Guidelines for Federal
Workplace Drug Testing Programs (69
FR 19644) dated April 13, 2004, and for
the information provided by laboratories
for the National Laboratory Certification
Program (NLCP).
The Federal Drug Testing Custody
and Control Form is used by all Federal
agencies and employers regulated by the
Department of Transportation to
document the collection and chain of
custody of urine specimens at the
collection site, for laboratories to report
results, and for Medical Review Officers
to make a determination. The Federal
Drug Testing Custody and Control Form
approved by OMB three years ago is
being resubmitted for OMB approval
without any revision.
Prior to an inspection, a laboratory is
required to submit specific information
regarding its laboratory procedures.
Collecting this information prior to an
inspection allows the inspectors to
thoroughly review and understand the
laboratory’s testing procedures before
arriving at the laboratory.
The NLCP application form has not
been revised compared to the previous
form.
E:\FR\FM\22FEN1.SGM
22FEN1
]]>Agencies
[Federal Register Volume 71, Number 35 (Wednesday, February 22, 2006)]
[Notices]
[Page 9136]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-1642]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Statement of Organization, Functions, and Delegations of
Authority
Part N, National Institutes of Health, of the Statement of
Organization, Functions, and Delegations of Authority for the
Department of Health and Human Services (HHS) (40 FR 22859, May 27,
1975, as amended most recently at 69 FR 64081, November 3, 2004, and
redesignated from Part HN as Part N at 60 FR 56606, November 9, 1995),
is amended as set forth below to reflect the reorganization of the
National Human Genome Research Institute, Division of Intramural
Research, by establishing (1) the Molecular Neurogenetics Section in
the Medical Genetics Branch and (2) the Vascular Biology Section in the
Genome Technology Branch. The sections are transferring from,
respectively, the National Heart, Lung, and Blood Institute and the
National Institute of Mental Health.
Section N-B, Organization and Functions, under the heading National
Human Genome Research Institute (N4, formerly HN4), Division of
Intramural Research (N45, formerly HN45) is amended as follows:
(1) In the Genome Technology Branch (N455, formerly HN455),
immediately after the paragraph on Genomic Functional Analysis Section
(N4556, formerly HN 4556), insert the following:
Vascular Biology Section (N4557, formerly HN 4557). Conducts
clinical and laboratory investigations in the molecular mechanisms of
cardiovascular disease including vascular cell biology, gene therapy,
and cell cycle regulation of vascular cells.
(2) In the Medical Genetics Branch (N456, formerly HN456),
immediately after the paragraph on Vertebrate Embryology Section
(N4567, formerly HN4567), insert the following:
Molecular Neurogenetics Section (N4568, formerly HN 4568). (1)
Conducts clinical and basic research into the factors contributing to
the phenotypic variation observed in monogenic diseases, using Gaucher
disease as a prototype disorder; (2) investigates the relationship
between Gaucher disease and parkinsonism; and (3) explores new
therapeutic approaches for Gaucher disease.
Delegations of Authority
All delegations and redelegations of authority to officers and
employees of NIH that were in effect immediately prior to the effective
date of this amendment and are consistent with this amendment shall
continue in effect, pending further redelegation.
Dated: February 8, 2006.
Elias A. Zerhouni,
Director, National Institutes of Health.
[FR Doc. 06-1642 Filed 2-21-06; 8:45 am]
BILLING CODE 4140-01-M
